Autologous stem cell transplantation (ASCT) became standard of care for patients with multiple myeloma (MM) under the age of 65 years. We routinely perform ASCT for newly diagnosed MM since 1996 in our department.
We retrospectively analyzed all 285 transplants in 185 patients done for MM from January 1996 till December 2010. There is a trend towards better survival, when new drugs are incorporated at any time in the course of the disease.
This fact supports hypothesis that use of these drugs with ASCT should translate into better long-term outcome.